NEUROLOGY
Yeh EA and Sormani MP
Neurology. 2020 Mar 17;94(11):465-466
DOI: https://doi.org/10.1212/WNL.0000000000009091
The emergence of highly effective therapies for multiple sclerosis (MS) has led to heightened attention to finding metrics sensitive to disease progression and activity. The neurologic examination alone cannot reliably assess ongoing MS disease activity, as new clinical findings emerge only with the involvement of eloquent areas of the CNS. Furthermore, multiple studies have shown the ability of MRI to assess MS disease activity and progression1 but at great expense of time and resources. Thus a noninvasive marker of progression and response to therapy remains an unmet need. In recent years, attention has fallen on the potential clinical utility of levels of neurofilaments (Nf), proteins that maintain neuronal caliber as part of the axoskeleton of neurons, and comprise light, medium, and heavy chains. The most abundant of these 3 proteins, Nf light chain (NfL), has emerged as a promising marker of neuroaxonal destruction. Recent technology using the single molecule array (Simoa) platform has allowed for the rapid, sensitive, and reproducible readout of NfL.2 This marker exhibits dynamic changes that correlate with neurodegeneration in diseases such as amyotrophic lateral sclerosis,3 amyotrophic lateral sclerosis–frontotemporal dementia,4 and Alzheimer disease, among others, and may also predict the emergence of Alzheimer disease in presymptomatic individuals.5 In MS, studies have shown an association of serum, plasma, or CSF NfL with disease activity and progression.6 We now face a number of questions: Can this marker be used to assess therapy efficacy in clinical trials? Can it help us in clinical decision-making for individual patients with MS?
Related Posts
Neurology
Comparative Spatial Analyses of the Tumor Immune Landscape in Mouse Models of Glioblastoma Using the PhenoCode Discovery Mouse Neuro Panel and Customized Markers
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Development of a Spatial Metabolic Map of Immunotherapy Sensitive and Resistant Cutaneous Skin Carcinoma
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Spatial Immunometabolic Profiling of Non-Small Cell Lung Cancer Reveals Distinct Immune Exclusion Patterns and Functional Niches
Analytical validation of a multiplex immunofluorescence 7-Biomarker Immunoprint® assay on the Akoya PhenoImager HT platform for stage I/II Melanoma
Neurology
Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Clinical validation of the LucentAD p-Tau 217 as a lab developed test (LDT) for clinical use
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…
Neurology
Discovering novel plasma biomarkers for ischemic stroke: Lipidomic and metabolomic analyses in an aged mouse model
Journal of Lipid Research | August 2, 2024 Becktel DA, Frye JB, Le EH, Whitman SA, Schnellmann RG, Morrison HW, Doyle KP. J Lipid Res. 2024 https://doi.org/10.1016/j.jlr.2024.100614 Abstract Ischemic stroke…